The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Age: 18 years - 66+
Gender: All
We've found 1 total result for "Arthritis Rheumatoid".